CSL News & Analysis

The ASX's biggest healthcare name saw its shares fall after reporting first-half results.

CSL's Behring division shone but markets were left underwhelmed by the company's guidance for 2025.

We heard from some of the heavy weights in the ASX 200 including CBA and CSL.

The ASX 200's third biggest company reports earnings on Tuesday. Here's what Morningstar's CSL analyst Shane Ponraj will be looking out for.

Our thoughts on how to take advantage of earnings season

And what do our analysts think of the stocks and ETF?

How our analyst views the shares after the clinical trial set-back.

Stock markets are highly efficient in the long run yet share prices can fluctuate wildly near term. The art of investing is buying quality stocks...

Thomas Rowe Price Jnr shocked Wall Street in the mid-60s by presciently selling growth stocks and buying real assets. His warnings to growth...

Schroders' Australian equity team say investors piling into tech stocks again are ignoring a turning point in markets.